Shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA – Get Free Report) have received a consensus recommendation of “Hold” from the nine ratings firms that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $21.1111.
A number of analysts have issued reports on SBRA shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $22.00 price target on shares of Sabra Healthcare REIT in a report on Monday, December 15th. Wall Street Zen cut Sabra Healthcare REIT from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Truist Financial upped their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Weiss Ratings reissued a “buy (b)” rating on shares of Sabra Healthcare REIT in a report on Thursday, January 22nd. Finally, UBS Group initiated coverage on shares of Sabra Healthcare REIT in a report on Tuesday, November 18th. They issued a “neutral” rating and a $20.00 target price for the company.
View Our Latest Research Report on Sabra Healthcare REIT
Institutional Trading of Sabra Healthcare REIT
Sabra Healthcare REIT Stock Down 0.4%
Shares of Sabra Healthcare REIT stock opened at $20.17 on Thursday. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.92. Sabra Healthcare REIT has a 52-week low of $15.60 and a 52-week high of $20.54. The company has a market capitalization of $5.03 billion, a P/E ratio of 31.52, a P/E/G ratio of 1.42 and a beta of 0.67. The company has a 50 day moving average of $19.04 and a 200 day moving average of $18.77.
Sabra Healthcare REIT (NASDAQ:SBRA – Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The real estate investment trust reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The firm had revenue of $201.35 million during the quarter, compared to analyst estimates of $201.97 million. Sabra Healthcare REIT had a net margin of 20.09% and a return on equity of 5.66%. Sabra Healthcare REIT’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.36 earnings per share. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. As a group, research analysts forecast that Sabra Healthcare REIT will post 1.45 EPS for the current fiscal year.
Sabra Healthcare REIT Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 27th. Shareholders of record on Friday, February 13th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $1.20 annualized dividend and a dividend yield of 5.9%. Sabra Healthcare REIT’s dividend payout ratio (DPR) is presently 187.50%.
More Sabra Healthcare REIT News
Here are the key news stories impacting Sabra Healthcare REIT this week:
- Positive Sentiment: Company issued FY‑2026 EPS guidance of $1.550–$1.590, well above the consensus cited in releases (~$1.06), signaling management expects stronger earnings power next year. Sabra Reports Fourth Quarter 2025 Results; Introduces 2026 Guidance
- Positive Sentiment: Q4 operating metrics showed growth in key cash flow measures: FFO $0.36 and AFFO $0.37, and revenue grew ~16% year-over-year to ~$201M — supports the raised FY outlook if trends persist. Sabra Reports Fourth Quarter 2025 Results; Introduces 2026 Guidance
- Neutral Sentiment: Management will attend Citi’s Global Property CEO Conference (Mar 1–4), providing investors an opportunity for additional color on guidance assumptions and portfolio strategy. Investor meetings could reduce uncertainty if management addresses outstanding questions. Sabra Health Care REIT, Inc. to Attend Citi’s 2026 Global Property CEO Conference
- Negative Sentiment: GAAP net income per diluted share for Q4 was $0.11, missing analyst estimates (~$0.37) and down from $0.36 a year ago — a near-term earnings disappointment that likely pressured the stock. Sabra: Q4 Earnings Snapshot / Earnings Release
- Negative Sentiment: Analyst commentary (BMO) flagged soft FFO outlook and uncertainty tied to an RCA loan, supporting a Hold rating — these risks could keep investor sentiment cautious until resolution or clearer guidance detail. Sabra Healthcare REIT: Solid SHOP Momentum Offset by Soft FFO Outlook and RCA Loan Uncertainty
Sabra Healthcare REIT Company Profile
Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.
Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.
Recommended Stories
- Five stocks we like better than Sabra Healthcare REIT
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Sabra Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
